Kiora licenses South Korean rights for KIO-301 to CKD for $1M upfront plus milestones and royalties

KIORA PHARMACEUTICALS INC

$1M upfront payment from CKD for exclusive South Korean rights to KIO-301 for retinitis pigmentosa and other ophthalmic indications.
Eligible for development, regulatory, and sales milestone payments plus double-digit royalties on net sales in South Korea.
CKD to handle development and commercialization in South Korea; partners Théa, Senju, and CKD to coordinate single global Phase 3 trial.
Kiora to focus on KIO-104 and ion channel modulators; evaluating strategic transactions to expand pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.